Siasos Gerasimos, Mourouzis Konstantinos, Oikonomou Evangelos, Tsalamandris Sotirios, Tsigkou Vasiliki, Vlasis Konstantinos, Vavuranakis Manolis, Zografos Thodoris, Dimitropoulos Stathis, Papaioannou Theodore G, Kalampogias Aimilios, Stefanadis Christodoulos, Papavassiliou Athanasios G, Tousoulis Dimitris
Mikras Asias 75 str, 115 27, Athens, Greece.
Curr Pharm Des. 2015;21(28):4016-34. doi: 10.2174/1381612821666150826094156.
Abdominal aortic aneurysm is a vascular disease which, despite the fact that it shares common risk factors with atherosclerosis, develops in parallel but as a partly independent process, through different pathogenic mechanisms. The pathogenic mechanisms involve metalloproteinase and collagenase activation, median and adventitial degradation, elastin lysis, vascular smooth cells transformation and apoptosis, collagen production and lysis imbalance combined with excessive inflammatory infiltration. Endothelial cells respond to a number of stimulating factors, including smoking, hypertension and AT1 receptor stimulation and non-uniform distribution of wall stress. Their ability to produce NO is crucial in order to adapt. Endothelial cells contribute to AAA development due to increased oxidative stress which is partly mediated by impaired NO bioavailability due to endothelial dysfunction and NADPH oxidase overexpression. In addition, they express several molecules among which adherence molecules, selectins, endothelin-1, regulating inflammatory infiltration and oxidative stress. Inflammatory cells consist of monocytes, polymorphonuclear neutrophils and lymphocytes and they are involved in the degrading process in the aortic wall by secreting proteolytic enzymes or by releasing interleukins which mediate the inflammation response. Endothelial dysfunction and arterial stiffness reflect on indices like FMD, carotid-femoral PWV and augmentation index, sometimes with controversial results. At present, surgical treatment is the only option provided in patients with large AAA, in particular. Focusing on the emerging role of endothelial cells in AAA pathology may contribute in creating new therapeutic options in a disease which has not yet a well-accepted, implemented pharmaceutical treatment.
腹主动脉瘤是一种血管疾病,尽管它与动脉粥样硬化有共同的危险因素,但却是通过不同的致病机制平行发展且部分独立的过程。致病机制包括金属蛋白酶和胶原酶激活、中膜和外膜降解、弹性蛋白溶解、血管平滑肌细胞转化和凋亡、胶原蛋白生成与溶解失衡以及过度的炎症浸润。内皮细胞对多种刺激因素作出反应,包括吸烟、高血压、AT1受体刺激以及壁应力的不均匀分布。它们产生一氧化氮(NO)的能力对于适应至关重要。内皮细胞由于氧化应激增加而促进腹主动脉瘤的发展,氧化应激部分是由内皮功能障碍导致的NO生物利用度受损和NADPH氧化酶过表达介导的。此外,它们表达多种分子,其中包括黏附分子、选择素、内皮素-1,这些分子调节炎症浸润和氧化应激。炎症细胞由单核细胞、多形核中性粒细胞和淋巴细胞组成,它们通过分泌蛋白水解酶或释放介导炎症反应的白细胞介素参与主动脉壁的降解过程。内皮功能障碍和动脉僵硬度反映在诸如血流介导的舒张功能(FMD)、颈股脉搏波速度(PWV)和增强指数等指标上,有时结果存在争议。目前,手术治疗尤其是大腹主动脉瘤患者的唯一选择。关注内皮细胞在腹主动脉瘤病理中的新作用可能有助于为这种尚未有广泛接受和实施的药物治疗的疾病创造新的治疗选择。